Journal article

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.

Kenji M Fujihara, Mariana Corrales Benitez, Carlos S Cabalag, Bonnie Z Zhang, Hyun S Ko, David S Liu, Kaylene J Simpson, Ygal Haupt, Lara Lipton, Sue Haupt, Wayne A Phillips, Nicholas J Clemons

Mol Cancer Ther | Published : 2021

Abstract

APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and is promoted as a mutant-p53 reactivation therapy. Currently, the detection of at least one TP53 mutation is an inclusion criterion for patient selection into most APR-246 clinical trials. Preliminary results from our phase Ib/II clinical trial investigating APR-246 combined with doublet chemotherapy [cisplatin and 5-fluorouracil (5-FU)] in metastatic esophageal cancer, together with previous preclinical studies, indicate that TP53 mutation status alone may not be a sufficient biomarker for APR-246 response. This study aims to identify a robust biomarker for response to APR-246. Correlation analysis..

View full abstract